Royal Bank of Canada’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-503
Closed -$1K 8318
2021
Q4
$1K Hold
503
﹤0.01% 7601
2021
Q3
$1K Sell
503
-1,925
-79% -$6.4K ﹤0.01% 7575
2021
Q2
$9K Buy
2,428
+779
+47% +$2.67K ﹤0.01% 6927
2021
Q1
$6K Buy
1,649
+1,309
+385% +$24.7K ﹤0.01% 7018
2020
Q4
$7K Buy
340
+310
+1,033% +$4.78K ﹤0.01% 6563
2020
Q3
$0 Buy
30
+14
+88% +$397 ﹤0.01% 7147
2020
Q2
$1K Sell
16
-32
-67% -$1.04K ﹤0.01% 6545
2020
Q1
$1K Sell
48
-551
-92% -$16.1K ﹤0.01% 6562
2019
Q4
$19K Buy
+599
New +$18.6K ﹤0.01% 5886
2019
Q1
Sell
-51
Closed -$1K 7247
2018
Q4
$1K Sell
51
-87
-63% -$1.35K ﹤0.01% 6645
2018
Q3
$3K Buy
138
+15
+12% +$306 ﹤0.01% 6464
2018
Q2
$3K Buy
123
+116
+1,657% +$2.7K ﹤0.01% 6208
2018
Q1
$0 Buy
+7
New +$165 ﹤0.01% 6989

Other funds holding ODT

Royal Bank of Canada's ODT Position: Q1 2022 in Review

Royal Bank of Canada sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 503 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in ODT in Q1 2018 and held it in 13 quarters. The position peaked at $19K in Q4 2019. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Royal Bank of Canada reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 503 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Royal Bank of Canada first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
  • Royal Bank of Canada's Odonate Therapeutics, Inc. Common Stock position peaked at $19K in Q4 2019.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Royal Bank of Canada's 13F filing for Q1 2022, filed 16 May 2022.